Elite Pharmaceuticals Q2 FY2023: Revenue $16.3M (+4% YoY), Net Income $1.82M

ELITE PHARMACEUTICALS INC /NV/

2023-Q2 EPS reported $0.00 revenue$16,258,671

Consolidated six-month revenue $16.3M, up 4% YoY vs prior year.
Operating profit $2.1M; net income $1.82M for the six-month period.
Revenue growth attributed to generic immediate-release and extended-release Adderall.
Conference call on Nov 15, 2022 at 11:30 AM EST; dial-in 1-800-346-7359.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.